Quest Diagnostics (DGX) SVP reports 49-share dividend reinvestment

Rhea-AI Filing Summary

Quest Diagnostics senior executive Patrick Plewman, SVP for Diagnostic Services, reported a small acquisition of company common stock. On April 20, 2026, he acquired 49 shares at $194.699 per share through a dividend reinvestment plan administered by his broker.

Following this transaction, Plewman directly holds 15,247 Quest Diagnostics shares. The filing notes that these dividend reinvestment plan shares are eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report the acquisition early on this Form 4.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Plewman Patrick

Role SVP for Diagnostic Services

Type	Security	Shares	Price	Value
L	Common Stock	49	$194.699	$10K

Holdings After Transaction: Common Stock — 15,247 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 49 shares Acquisition price: $194.699 per share Post-transaction holdings: 15,247 shares

3 metrics

Shares acquired 49 shares Common Stock acquired on April 20, 2026

Acquisition price $194.699 per share Price for 49 Quest Diagnostics shares

Post-transaction holdings 15,247 shares Total Quest Diagnostics shares held directly after transaction

Key Terms

dividend reinvestment plan, Rule 16a-6, Form 5, small acquisition

4 terms

dividend reinvestment plan financial

"Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Rule 16a-6 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

Form 5 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.

small acquisition financial

"transaction_code_description": "Small acquisition under Rule 16a-6"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plewman Patrick

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP for Diagnostic Services

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		L	V	49(1)	A	$194.699	15,247	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney in Fact for Patrick Plewman	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Quest Diagnostics (DGX) report for Patrick Plewman?

Quest Diagnostics reported that SVP for Diagnostic Services Patrick Plewman acquired 49 shares of common stock. The shares were obtained on April 20, 2026, through a dividend reinvestment plan administered by his broker and disclosed on a Form 4 filing.

How many Quest Diagnostics (DGX) shares does Patrick Plewman hold after this transaction?

After the reported transaction, Patrick Plewman directly holds 15,247 shares of Quest Diagnostics common stock. This total reflects the addition of 49 shares acquired via a dividend reinvestment plan on April 20, 2026, as disclosed in the Form 4 filing.

What is the price and size of Patrick Plewman’s recent Quest Diagnostics (DGX) share acquisition?

Patrick Plewman acquired 49 shares of Quest Diagnostics common stock at a price of $194.699 per share. The transaction was executed through a dividend reinvestment plan and reported as a small acquisition under Rule 16a-6 on Form 4.

Why was this Quest Diagnostics (DGX) dividend reinvestment transaction reported on Form 4?

The filing notes that the dividend reinvestment plan shares were eligible for deferred reporting on Form 5 under Rule 16a-6. However, Patrick Plewman chose to report the small acquisition early on Form 4, providing more timely disclosure of the transaction.

What does Rule 16a-6 mean for Quest Diagnostics (DGX) insider transactions?

Rule 16a-6 allows certain small acquisitions, such as dividend reinvestment plan purchases, to be reported later on Form 5. In this case, Quest Diagnostics executive Patrick Plewman instead opted to disclose the 49-share acquisition immediately on Form 4.